DE60126324D1 - Pharmazeutisch wirksame isoindolinderivate - Google Patents

Pharmazeutisch wirksame isoindolinderivate

Info

Publication number
DE60126324D1
DE60126324D1 DE60126324T DE60126324T DE60126324D1 DE 60126324 D1 DE60126324 D1 DE 60126324D1 DE 60126324 T DE60126324 T DE 60126324T DE 60126324 T DE60126324 T DE 60126324T DE 60126324 D1 DE60126324 D1 DE 60126324D1
Authority
DE
Germany
Prior art keywords
pharmaceutically active
isoindoline derivatives
active isoindoline
alkyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126324T
Other languages
English (en)
Other versions
DE60126324T2 (de
Inventor
W Muller
I Stirling
Hon-Wah Man
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of DE60126324D1 publication Critical patent/DE60126324D1/de
Publication of DE60126324T2 publication Critical patent/DE60126324T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
DE60126324T 2000-11-14 2001-11-14 Pharmazeutisch wirksame isoindolinderivate Expired - Lifetime DE60126324T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US712550 2000-11-14
US09/712,550 US6458810B1 (en) 2000-11-14 2000-11-14 Pharmaceutically active isoindoline derivatives
PCT/US2001/044107 WO2002094180A2 (en) 2000-11-14 2001-11-14 Pharmaceutically active isoindoline derivatives

Publications (2)

Publication Number Publication Date
DE60126324D1 true DE60126324D1 (de) 2007-03-15
DE60126324T2 DE60126324T2 (de) 2007-11-15

Family

ID=24862586

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60138932T Expired - Lifetime DE60138932D1 (de) 2000-11-14 2001-11-14 Pharmazeutisch wirksame Isoindolinderivate
DE60126324T Expired - Lifetime DE60126324T2 (de) 2000-11-14 2001-11-14 Pharmazeutisch wirksame isoindolinderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60138932T Expired - Lifetime DE60138932D1 (de) 2000-11-14 2001-11-14 Pharmazeutisch wirksame Isoindolinderivate

Country Status (19)

Country Link
US (4) US6458810B1 (de)
EP (2) EP1733726B1 (de)
JP (1) JP4328536B2 (de)
KR (2) KR100881797B1 (de)
CN (1) CN1290501C (de)
AT (2) ATE432704T1 (de)
AU (1) AU2001297762B2 (de)
CA (1) CA2427619A1 (de)
CY (1) CY1106453T1 (de)
DE (2) DE60138932D1 (de)
DK (1) DK1341537T3 (de)
ES (2) ES2324174T3 (de)
HK (1) HK1060281A1 (de)
IL (1) IL155758A0 (de)
MX (1) MXPA03004219A (de)
NO (1) NO327125B1 (de)
NZ (2) NZ528078A (de)
PT (1) PT1341537E (de)
WO (1) WO2002094180A2 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HUP0102113A3 (en) * 1998-03-16 2003-03-28 Celgene Corp Warren 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
CA2430669C (en) * 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
ES2338534T3 (es) * 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
ATE440094T1 (de) * 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
MXPA04011310A (es) * 2002-05-17 2005-02-14 Celgene Corp Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
IL165254A0 (en) * 2002-05-17 2005-12-18 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ZA200503655B (en) 2002-11-06 2006-08-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1581205A1 (de) * 2002-11-18 2005-10-05 Celgene Corporation Verfahren zur verwendung undzusammensetzungen umfassend(+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamid
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
JP4943845B2 (ja) 2003-09-17 2012-05-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
ZA200603718B (en) * 2003-11-06 2007-09-26 Celgene Corp Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2005051942A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ZA200607799B (en) * 2004-03-22 2008-06-25 Celgene Corp Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CA2562715A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
JP2007532642A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
KR20070010184A (ko) * 2004-04-23 2007-01-22 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
KR20070057907A (ko) * 2004-09-03 2007-06-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법
MX2007005040A (es) * 2004-10-28 2007-06-19 Celgene Corp Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
MX2007006063A (es) * 2004-11-23 2007-07-11 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
KR20080026198A (ko) * 2005-06-30 2008-03-24 안트로제네시스 코포레이션 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
MX2007016290A (es) * 2005-06-30 2008-03-10 Celgene Corp Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona.
US7928280B2 (en) * 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
EP1919365A2 (de) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Okular-plug aus kollagen-biogewebe aus plazenta
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
CA2845095A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
MX343814B (es) 2005-10-13 2016-11-24 Anthrogenesis Corp Inmunomodulación usando celulas madre de la placenta.
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CN101374941A (zh) 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
NZ597223A (en) 2006-10-06 2013-09-27 Anthrogenesis Corp Native (telopeptide) placental collagen compositions
EP2129775A1 (de) 2007-02-12 2009-12-09 Anthrogenesis Corporation Hepatocyten und chondrocyten aus adhärenten plazentastammzellen sowie cd34+, cd45- plazentastammzellenangereicherte zellpopulationen
CN103356711A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
ES2601131T3 (es) 2007-03-20 2017-02-14 Celgene Corporation Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
ES2719931T3 (es) 2007-09-28 2019-07-16 Celularity Inc Supresión de tumor usando perfusato placentario humano y células asesinas naturales intermedias que provienen de placenta humana
CA2710196A1 (en) * 2007-12-20 2009-07-09 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
US20090171093A1 (en) * 2007-12-28 2009-07-02 Yoshio Takeuchi 3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
CN101531653B (zh) * 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
PT2411506T (pt) 2009-03-25 2019-03-19 Celularity Inc Supressão de tumores usando células assassinas naturais intermédias derivadas de placenta humana e compostos imunomoduladores
WO2010137547A1 (ja) 2009-05-25 2010-12-02 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
CA2786266A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
JP5937060B2 (ja) 2010-04-07 2016-06-22 セルジーン コーポレイション 呼吸器ウイルス感染症の治療方法
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
CA2867134C (en) 2011-03-28 2019-05-07 Sheila Dewitt 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140106390A1 (en) 2011-04-18 2014-04-17 Celgene Corporation Biomarkers for the treatment of multiple myeloma
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX357749B (es) 2011-06-01 2018-07-23 Anthrogenesis Corp Tratamiento contra el dolor utilizando células madre placentarias.
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN104717974A (zh) 2012-06-06 2015-06-17 比奥诺尔免疫有限公司 疫苗
ES2699810T3 (es) 2012-06-29 2019-02-12 Celgene Corp Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
NZ629456A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
JP2017523166A (ja) 2014-07-11 2017-08-17 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ヒト免疫不全ウイルスｉ（ｈｉｖ）の病理学的影響を減少及び／若しくは遅延させるか又は後天性免疫不全症候群（ａｉｄｓ）を発症するリスクを低減させる方法
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
PT3643709T (pt) * 2014-10-30 2021-12-20 Kangpu Biopharmaceuticals Ltd Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016210262A1 (en) 2015-06-26 2016-12-29 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3548083A1 (de) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Verfahren zur modulation von car-t-zellen
MX2019012975A (es) 2017-05-01 2020-08-03 Juno Therapeutics Inc Combinacion de una terapia celular y un compuesto inmunomodulador.
EP3630132A1 (de) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Erzeugnisse und behandlungsverfahren unter verwendung von adoptiver zelltherapie
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
US20200246393A1 (en) 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
US20210132042A1 (en) 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US20210070845A1 (en) 2017-12-15 2021-03-11 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
KR20200123155A (ko) 2018-02-21 2020-10-28 셀진 코포레이션 Bcma-결합 항체 및 이의 용도
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
AU2019381688A1 (en) 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
CA3120869A1 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN111499623B (zh) * 2020-04-01 2022-07-08 南京缘聚医药科技有限公司 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
KR20240001072A (ko) * 2022-06-24 2024-01-03 주식회사 아이비스바이오 신규한 포말리도마이드 유도체 및 이의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054654A (en) 1972-03-16 1977-10-18 Rhone-Poulenc, S.A. Isoindolin-1-one derivatives
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ES2529190T3 (es) 1996-07-24 2015-02-17 Celgene Corporation 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP0918746B1 (de) 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
DK0963200T3 (da) 1996-11-05 2005-10-24 Childrens Medical Center Præparater til inhibering af angiogenese omfattende thalidomid og et NSAID
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
HUP0102113A3 (en) 1998-03-16 2003-03-28 Celgene Corp Warren 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
ES2250121T3 (es) 1999-03-18 2006-04-16 Celgene Corporation 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
NZ521937A (en) 2000-03-31 2004-08-27 Celgene Corp Inhibition of cyclooxygenase-2 activity
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
ES2325916T3 (es) 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
AU2004296765B2 (en) 2003-12-02 2011-03-24 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ZA200607799B (en) 2004-03-22 2008-06-25 Celgene Corp Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

Also Published As

Publication number Publication date
JP2004520442A (ja) 2004-07-08
MXPA03004219A (es) 2004-04-20
PT1341537E (pt) 2007-03-30
WO2002094180A3 (en) 2003-02-27
DE60138932D1 (de) 2009-07-16
EP1341537A4 (de) 2004-01-28
ES2278685T3 (es) 2007-08-16
JP4328536B2 (ja) 2009-09-09
US20030069428A1 (en) 2003-04-10
US20060069126A1 (en) 2006-03-30
NO327125B1 (no) 2009-04-27
ES2324174T3 (es) 2009-07-31
DE60126324T2 (de) 2007-11-15
KR20030063383A (ko) 2003-07-28
KR100881797B1 (ko) 2009-02-03
NZ526319A (en) 2005-05-27
KR20080107480A (ko) 2008-12-10
IL155758A0 (en) 2003-12-23
CY1106453T1 (el) 2011-10-12
NO20032074L (no) 2003-07-04
ATE432704T1 (de) 2009-06-15
AU2001297762B2 (en) 2006-09-07
EP1733726B1 (de) 2009-06-03
US7834033B2 (en) 2010-11-16
ATE352303T1 (de) 2007-02-15
CA2427619A1 (en) 2002-11-28
HK1060281A1 (en) 2004-08-06
NO20032074D0 (no) 2003-05-09
EP1733726A1 (de) 2006-12-20
EP1341537B1 (de) 2007-01-24
US6458810B1 (en) 2002-10-01
EP1341537A2 (de) 2003-09-10
NZ528078A (en) 2005-04-29
WO2002094180A2 (en) 2002-11-28
DK1341537T3 (da) 2007-05-29
US6762195B2 (en) 2004-07-13
CN1290501C (zh) 2006-12-20
CN1575174A (zh) 2005-02-02
US20040122052A1 (en) 2004-06-24
US7005438B2 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
DE60126324D1 (de) Pharmazeutisch wirksame isoindolinderivate
NO20161012A1 (no) Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
DE60040293D1 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
SE9900100D0 (sv) New compounds
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
DE69611315D1 (de) 5-Substituierte-3-(1,2,3,6-Tetrahydropyridin-4-yl) und 3-(Piperidin-4-yl)-1H-indole: 5-HT1F Agonisten
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
DE60118430D1 (de) Behandlung gastrointestinaler stroma-tumoren
YU17397A (sh) Mezilat trihidrat 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperazinil)1etil)-6-hloro-1,3-dihidro-2h-indol-2-ona
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
ATE253561T1 (de) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
MA25391A1 (fr) Inhibiteurs d'alcenyl et alcynyl metalloproteases.
IS5336A (is) 2-(4-Arýl eða heteróarýl-píperazín-1-ýlmetýl)-1H-indól afleiður
ATE316093T1 (de) Glucopyranosid-konjugate von 2-(4-hydroxy-phenyl)-1-(4-(2-amin-1-yl-ethoxy)- enzyl)-1h-indol-5-olen
DE69713571D1 (de) Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
ID28645A (id) KOMPOSISI-KOMPOSISI ORAL 8-KLORO-6, 11-DIHIDRO-11-(4-PIPERIDILIDENA)- 5H-BENZO(5,6) SIKLOHEPTA (1,2-b) PIRIDINA
ITTO20000745A0 (it) Nuovi acidi naftilsolfonici e composti ad essi correlati utli come agonisti dell'assorbimento del glucosio.
TW200502219A (en) Pharmaceutically active isoindoline derivatives
IS5731A (is) 4, 5, 6 og 7-indól og indólín afleiður, framleiðsla þeirra og notkun
CY1106540T1 (el) Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες
DK1239861T3 (da) Kombinationaf cyamemazin og et atypisk neuroleptikum
PT1027891E (pt) Antagonista de neuropeptido y
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition